Cardioxyl Pharmaceuticals

Acquired

Towson, United States · Founded 2005 · $42.5M raised

Headquarters
Towson, Maryland
Employees
11–50
Founded
2005
Business Model
B2B
Total Funding
$42.5M
Last Round
$14.5M Series ANov 2012
Rounds
2
Acquired by
Bristol-Myers Squibb CompanyJan 2015

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Cardioxyl Pharmaceuticals was a private biotechnology company focused on the discovery and development of novel therapeutic agents for cardiovascular disease, particularly heart failure. Its lead asset, CXL-1427, was a nitroxyl (HNO)-releasing prodrug with a novel mechanism of action that advanced to Phase 2 clinical trials for acute decompensated heart failure. Bristol-Myers Squibb acquired Cardioxyl in November 2015 for $300 million upfront and up to $1.78 billion in milestone payments.

Summary

Cardioxyl Pharmaceuticals is a Biotech company based in Towson, United States, founded in 2005. It has raised $42.5M in total across 2 rounds, most recently a $14.5M Series A round in Nov 2012. Investors include New Enterprise Associates, The Aurora Funds and Bristol Myers Squibb.

Funding History

AcquisitionJan 2015

Sign up to see all 3 events

Funding: Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Cardioxyl Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/cardioxyl-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/cardioxyl-pharmaceuticals" alt="Cardioxyl Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>